Trodelvy is an exciting new drug that could give certain women living with incurable triple negative secondary breast cancer the hope of more time. More time to enjoy with loved ones and to do things that matter most to them.
Trodevly has already been approved in Scotland, but was provisionally rejected for use on the NHS in England in April. In response, we launched an open letter, calling on pharmaceutical company, Gilead, NICE and NHS England to find a solution to make Trodelvy available to the women who need it.
Sign up for campaign updates
Our open letter was signed by 114,366 people. We want to say a massive thank you to everybody who added their name and helped us send the strongest message possible that this drug needs to be made routinely available on the NHS..
We hope to hear a final decision on whether NICE has approved Trodelvy for routine use on the NHS towards the end of June. To find out about the outcome of the campaign and keep up to date with our other work, please sign up for campaign updates below
'I want other women to be able to have the same chance to benefit from Trodelvy. This drug gives me hope of more time and doing things that matter most to me, like walking my dog and spending time with my family. It’s absolutely vital that others get the same opportunity and that Trodelvy is now made available on the NHS.’
Frequently asked questions
What is Trodelvy?
Trodelvy which you may also hear referred to as sacituzumab govitecan is a targeted (biological therapy). It delivers a chemotherapy drug straight to cancer cells which have the protein Trop-2 on their surface. This can be the case in many types of cancer, including breast cancer.
Who is it for?
This treatment is suitable for patients with unresectable locally advanced or secondary triple negative breast cancer who have had at least two prior therapies.
What is the problem?
We are concerned patients living with incurable triple negative secondary breast cancer may be facing a delay before they can access Trodelvy on the NHS, which could provide them with the hope of more time to spend with loved ones.
While the drug is set to be licensed for use soon, it won’t actually be assessed for use on the NHS in England until much later this year with a decision then reached next year– meaning a wait of many months before the women who could benefit from it can access it.
To avoid this delay, we are urging Gilead, the company who own Trodelvy, to provide the drug free of charge on the NHS for a limited time until it is approved for routine use.
What are you hoping to achieve?
We want to see eligible patients with triple negative secondary breast cancer accessing Trodelvy on the NHS between licensing and a NICE decision. For this to happen, we need NHS England and the company, Gilead, to agree an interim access agreement and in particular, Gilead needs to be willing to give the drug away free of charge for a time limited period.
We know it is possible because a similar agreement was reached with a lung cancer drug earlier this year.
Why are you targeting Gilead?
Because Gilead, who own Trodelvy, can provide a short-term solution to this problem. Gilead could do the right thing and choose to provide the drug free of charge on the NHS, on a short-term basis, until it is approved for routine use on the NHS.
We know this is possible because in May 2021, an interim access agreement was reached for a lung cancer drug between another company and NHS England enabling patients to access the treatment following licensing and prior to a NICE recommendation so it shows that it is possible to make Trodelvy available too.
Is this campaign just about England? What about the Devolved nations?
While the petition is specifically calling on Gilead to reach an agreement with NHS England to provide Trodelvy for free until it is assessed for routine use on the NHS by NICE, we believe it’s crucial that patients in Wales, Scotland and Northern Ireland also have access to Trodelvy. That’s why we want Gilead and NHS decision-makers in the devolved nations to work together and explore every possible solution for patients getting early access to Trodelvy.
We believe that if an agreement can be reached in England, it will make it much more likely for similar agreements to be reached in Northern Ireland, Scotland and Wales.
Can I access Trodelvy now?
The drug company that makes Trodelvy, Gilead, has introduced a pre-reimbursement access scheme which means that some patients will now be able to access Trodelvy free-of-charge following licensing and ahead of a NICE decision. However, we are concerned because the scheme is limited in numbers, so currently it cannot guarantee access to this important drug for all eligible patients until a NICE decision. That’s why we are continuing our #TimeforTrodelvy campaign to ensure all eligible patients can access it, when they need it. To access this scheme, speak to your clinician as they will need to put a request into the drugs company to access the drug.